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Cell replacement is heralded as an attractive 
therapeutic option for the treatment of heart 
failure (for review see reference 1), a disorder 
characterized by a very poor 5-yr survival 
rate. The only eff  ective treatment is currently 
achieved by solid organ transplantation.
We and others have demonstrated that cel-
lular replacement therapy using contractile cells 
is a valid alternative (1). At the moment there 
are contrasting views as to which cell type may 
be best suited for cellular cardiomyoplasty 
(1, 2). In the past few years, attention has fo-
cused on the “transdiff  erentiation” of BM cells 
into cardiomyocytes (3) as a source of cardio-
myocyte replacement in the damaged heart. 
However, recent studies in mice question these 
fi  ndings (4, 5), and new evidence suggests that 
potentially paracrine eff  ects (6) and/or neovas-
cularization (7), not neogenesis of the myocar-
dium, may have benefi  cial eff  ects. Thus, it is 
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Cellular cardiomyoplasty is an attractive option for the treatment of severe heart failure. It is, 
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ment into cardiomyocytes and their long-term engraftment and tumorigenicity are still 
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enhanced green fl  uorescent protein cassettes under control of a cardiac-specifi  c promoter. 
Puromycin   selection resulted in a highly purifi  ed (>99%) cardiomyocyte population, and the 
yield of cardiomyocytes increased 6–10-fold because of induction of proliferation on purifi  -
cation. Long-term engraftment (4–5 months) was observed when co-transplanting selected 
ES cell–derived cardiomyocytes and fi  broblasts into the injured heart of syngeneic mice, and 
no teratoma formation was found (n = 60). Although transplantation of ES cell–derived 
cardiomyocytes improved heart function, BM cells had no positive effects. Furthermore, no 
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Hence, our results demonstrate that ES-based cell therapy is a promising approach for the 
treatment of impaired myocardial function and provides better results than BM-derived cells. CORRESPONDENCE
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still unclear whether and to which degree transplantation of 
BM cells results in improvement of defective heart function 
after infarction.
Because embryonic stem cells (ES cells) can diff  erentiate 
into all diff  erent cell types (pluripotency), they represent an 
excellent starting population for the generation of cells in re-
generative medicine (for review see references 1, 8). How-
ever, there are still substantial hurdles to overcome before ES 
cells can be exploited for therapeutic purposes. A principle 
problem in particular for muscle cells (9) is the diffi   culty in 
obtaining suffi   cient quantities of high quality cells. Although 
earlier studies addressed the purifi  cation (10, 11) and trans-
plantation of ES cell–derived cardiomyocytes into a very 
small cohort of mice (10), the best preparation to ensure 
long-term engraftment, their fate after transplantation, and 
the impact of these cells on heart function in vivo is un-
known. Alternative approaches using undiff  erentiated mouse 
ES cells in xenomodels appear inconclusive (12, 13), because 
cell diff  erentiation is known to be critically dependent on 
signals provided from the host tissue. Most importantly, xen-
omodels bear little predictability with respect to tumorige-
nicity (14, 15), which is still a very substantial problem with 
ES cell–based transplantation strategies, because teratomas are 
rejected in xenografts (16).
Thus, the diff  erent cellular sources for improvement of 
cardiac function remain of considerable interest to explore 
(1), but few if any studies have directly examined the poten-
tial of diff  erent cell types in the same models. We have there-
fore determined in the present study fate and functional 
impact of BM cells, as well as noncardiomyocytes and ES 
cell–derived cardiomyocytes, after transplantation into in-
farcted mouse hearts.
RESULTS
Fate and functional impact of BM cells in the infarcted 
mouse heart
We have used cryoinjury (17) or left coronary artery (LCA) 
ligation (Fig. 1 A) to induce large left ventricular infarctions. 
For hemodynamic studies the fi  rst injury model is preferable, 
as highly reproducible lesions are generated even in the mouse 
(17). Enhanced GFP+ (EGFP+) BM cells (3 × 106) were in-
jected into the center and the border zone of the infarction 
as previously described (3, 5), and hearts were analyzed 3–4 
wk later. Catheterization revealed no improvement of left 
  ventricular ejection fraction (LVEF) and other functional pa-
rameters (not depicted) compared with sham-injected mice 
(Fig. 1 O and Table S1, available at http://www.jem.org/cgi/
content/full/jem.20061469/DC1), whereas morphological 
analysis of cryosections revealed considerable engraftment 
of EGFP+ cells in the scar region (Fig. 1 D). To test whether 
a higher percentage of BM-derived stem cells is required to 
enhance left ventricular function (LVF), recipient mice were 
lethally irradiated, reconstituted with transgenic BM cells (5), 
and, after assessment of good engraftment (>80%), heart in-
farction (cryoinfarction or LCA ligation) and cytokine mobi-
lization were performed. The integration of EGFP+ cells in 
and around the injury site was massive 3–4 wk after operation 
in both lesion models (Fig. 1, B and C) and clearly higher 
than after direct injection (Fig. 1 D). However, measure-
ments of LVEF also yielded no improvement in these mice 
compared with the sham-injected controls after cryoinjury 
(Fig. 1 P and Table S1) and after LCA ligation (49.6 ± 6.1% 
[n = 4] in the mobilized vs. 54.6 ± 3.3% [n = 3] in the non-
mobilized control group; Table S1). Note that lesion sizes in 
LCA-infarcted animals can vary.
To determine in more detail the eff  ects of directly inject-
ing or mobilizing BM cells, hearts were harvested and ana-
lyzed by immunohistochemistry. In accordance with function, 
no obvious morphological diff  erences were noted in cryo-
injured and LCA-ligated versus control hearts. Cytokine-
  induced mobilization led also to infi  ltration of EGFP+ cells in 
intact myocardium (Fig. 1 E). Two diff  erent shapes of EGFP+ 
cells, round and more elongated, were identifi  ed; the latter 
was more frequent in the border zone of the lesion and in the 
intact myocardium (Fig. 1, G and H). The EGFP+ cells in 
the scar region (Fig. 1 F) and in the border zone (Fig. 1, G 
and H) were positive for the panhematopoietic marker CD45 
and negative for the muscle marker cardiac α-actinin. Con-
sistent with our earlier fi  ndings (5), a few morphologically 
intact EGFP+ cardiomyocytes originating through cell fusion 
were found. Large (Fig. 1 I) and small (Fig. 1, J and K) vessels 
in and around the scar region were stained with the endothe-
lial markers platelet/endothelial cell adhesion molecule 
(PECAM) or von Willebrand factor (unpublished data) and 
with α–smooth muscle actin (ASMAC), and all theses vessels 
were found to be EGFP−. Some of the small vessels lacked 
the smooth muscle layer (Fig. 1 J), which is a typical fi  nding 
for newly formed vessels in the lesion. Occasionally, EGFP+/
PECAM−/ASMAC− cells were detected in the lumen or 
even below the endothelial cell layer of small vessels (Fig. 1 K), 
indicating transmigrating hematopoietic cells.
To further exclude potential initiation or ongoing car-
diac transdiff   erentiation of EGFP+ cells with a diff  erent 
technique than immunohistochemistry, we characterized the 
functional expression of ion channels using patch clamp; this 
technique provides a highly sensitive readout of the func-
tional and developmental status of cells (18). Isolated cells 
were obtained from mobilized hearts after collagenase treat-
ment, and both EGFP+ and EGFP− cells were investigated. 
We found that all EGFP+ cells had a small membrane capac-
itance (7.1 ± 0.1 pA/pF; n = 7) and functionally did not 
express voltage-dependent inward currents (n = 15; Fig. 1 N, 
right), a hallmark of cardiomyocytes starting from early 
  embryonic development (Fig. 1 M, inset) (9, 18). In con-
trast, native cardiomyocytes harvested from the same hearts 
were EGFP−, had distinct cross-striation (Fig. 1 N, inset), a 
large membrane capacitance (127.2 ± 22.4 pA/pF; n = 7), 
and expressed INa and ICa (Fig. 1 M). Accordingly, action 
potentials could be evoked by depolarizing voltage ramps in 
EGFP− (n = 3; Fig. 1 L) but not EGFP+ cells (n = 11; Fig. 
1 N, left), where only outwardly rectifying K+ currents were 
found (n = 15; Fig. 1 N, right).JEM VOL. 203, October 2, 2006  2317
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Figure 1.  Engraftment and characterization of BM cells after 
direct injection or cytokine mobilization in the infarcted heart, 
including impact on heart function. (A) Sirius red staining shows 
extended scar (red) formation in an infarcted heart 4 wk after LCA liga-
tion. (B–D) Engraftment of large numbers of EGFP+ cells after cytokine 
mobilization (B and C) and direct injection of BM cells (D) 4 wk after 
infarction. (E) Increased engraftment of EGFP+ cells in the border zone 
and the native myocardium after mobilization. (F–H) EGFP+ cells were 
CD45+ (Cy5, magenta; F and H) and α-actinin− (Cy3, red; F and G) 
within the scar (F) and in the border zone (G and H). (I–K) Large (I) and 
small (J and K) vessels in the infarcted area were PECAM+ (Cy3, red) and 
ASMAC+ (Cy5, magenta) but EGFP−; some small vessels lacked the 
smooth muscle layer (J). Note the EGFP+ transmigrating cell (K, inset). 
Nuclei were stained with Hoechst dye (blue). (L–N) Depolarizing current 
ramps (10 s) evoked action potentials in EGFP− cardiomyocytes (L) but 
not in EGFP+ cells (N, left). (M, inset; and N, right) Voltage ramps (−80 to 
+50 mV, 250 ms) evoked inward currents in adult (M) and embryonic 
(E9.5; M, inset) cardiomyocytes but not in EGFP+ cells (N, right). Images 
show transmission and fl  uorescent images of a patched cell (EGFP, 
green; CD45, red). (O and P). Statistics of LVEF 3–4 wk after infarction 
using catheterization. The values are normalized to data obtained from 
WT C57BL/6 mice (n = 6). Original data are listed in Table S1. Note that 
mice that underwent cytokine mobilization (P) show reduced LVEF, which 
was likely caused by irradiation (P = 0.95 [O] and 0.77 [P], respectively). 
Bars: (A) 900 μm; (B) 550 μm; (C) 250 μm; (D) 300 μm; (E) 400 μm; 
(F) 15 μm; (G and H) 20 μm; (I–K) 35 μm.2318  TRANSPLANTATION OF BM CELLS AND ES CELL–DERIVED CARDIOMYOCYTES | Kolossov et al.
Transplantation of undifferentiated ES cells and nonpurifi  ed 
ES cell–derived cardiomyocytes
Because we found no evidence for BM transplantation im-
proving cardiac function or diff  erentiation of BM cells into 
cardiomyocytes, endothelial cell, or smooth muscle cells, we 
next investigated ES cells as an alternative cellular source for 
cardiomyoplasty.
Because of contrasting earlier reports (12–14), we fi  rst 
  determined the tumorigenicity of undiff   erentiated ES cells 
by injecting 106 cells (n = 2) into the tail vein or 105 cells 
(n = 14) directly into infarcted hearts. Large tumor masses were 
detected in all syngeneic (n = 13) and 2 out of 3 allogeneic an-
imals within 4 wk (see Fig. 6 E). The onset of tumor growth 
occurred as early as 10 d after ES cell transplantation. Next, we 
excised beating EGFP+ areas from transgenic α–myosin heavy 
chain (α-MHC)–EGFP embryoid bodies (EBs) (9) to enrich 
for cardiomyocytes and reduce the number of undiff  erentiated 
ES cells. After injection (105 cells), tumor growth was still 
  detected in the majority of mice (fi  ve out of six; Fig. 2, A–C; 
and see Fig. 6 E) but with delayed onset. Histological analysis 
of the tumors revealed glandular (endoderm), squamous epi-
thelium (ectoderm), and cartilage (mesoderm) diff  erentiation 
(Fig. 2, D and E), hence typical histological features of tera-
tomas. These results indicated that highly purifi  ed ES cell–
  derived tissue preparations are required to minimize the risk 
for tumor generation.
Puromycin-based selection and induction of proliferation 
of ES cell–derived cardiomyocytes
To purify and identify ES cell–derived cardiomyocytes, we 
generated a bicistronic vector in which the cardiac-specifi  c 
promoter α-MHC drives the expression of both the puro-
mycin resistance gene and the EGFP cassette (Fig. 3 A, 
top). Two clones (αPIG10 and αPIG44) were chosen for 
further study and diff  erentiated in vitro using the hanging 
drop or mass culture protocol. The fi  rst clusters of EGFP+ 
cells were detected in the EBs on days 7–8 of development, 
and spontaneous beating began  12–24 h later. 10 μg/ml 
puromycin was added to the culture dishes on days 9–10 
(Fig. 3 A, left), and EGFP fl   uorescence and contractile 
  activity of the EGFP+ clusters intensifi  ed during the fi  rst 
24–72 h, indicating cardiomyocyte enrichment (Fig. 3 A, 
middle). After 6 d of puromycin treatment, most of the EBs 
consisted of strongly beating EGFP+ clusters of cardiac cells 
(Fig. 3 A, right). Similar results were obtained with both 
hanging drops and mass culture in vitro diff  erentiation pro-
tocols. Because the mass culture protocol typically yielded 
an order of magnitude more cardiomyocytes, it was used in 
all subsequent experiments.
As the cardiac cell mass appeared to increase during later 
puromycin selection (see Fig. 3 A and Video 1, available at 
http://www.jem.org/cgi/content/full/jem.20061469/DC1), 
we determined whether proliferation of ES cell–derived cardio-
myocytes underlies this phenomenon. We found that the num-
ber of EGFP+ cells increased dramatically during the fi  rst 3 d 
of puromycin selection and thereafter reached a plateau level 
yielding 6–10 times higher numbers of cardiomyocytes than in 
the untreated counterparts (n = 4; Fig. 3 B). We confi  rmed this 
observation by labeling cardiomyocytes in the S phase using 
BrdU for 24 h. We found that 32% of cardiomyocytes were 
BrdU+ by day 3 of puromycin treatment compared with only 
2% before the initiation of selection (Fig. 3, C and D). There-
after, their number decreased to  13%. In the untreated con-
trol cultures, no BrdU-labeled cardiomyocytes were detected at 
these stages of development (n = 2; Fig. 3 D). To estimate the 
size of the proliferative pool of cardiomyocytes, the BrdU label-
ing time was increased from 24 to 72 h beginning on the third 
day of puromycin treatment (n = 2). This protocol revealed 
that 37% of αPIG44- and 61% of αPIG10-derived cardiomyo-
cytes had entered the cell cycle during the labeling period. From 
these results, the cell cycle length was calculated to be 18 ± 4 h 
and that  50% of the cardiomyocytes cycled four to fi  ve times 
during the fi  rst 3 d of drug selection. This is in complete agree-
ment with numbers obtained by cell counting (see Fig. 3 B), 
which indicated a 6–10-fold increase in the total number of 
cardiomyocytes induced by purifi  cation.
Figure 2.  Teratoma formation after injection of undifferentiated 
ES cells and cut-out beating areas into the infarcted heart. 
(A) Opened mouse chest in situ. In the apical part of the heart, a large 
tumor mass was seen 68 d after injecting 105 cells obtained from EGFP+-
beating areas of EBs. (B) Periodic acid Schiff–stained cross sections of this 
tumor showed exophytic tumor growth. (C) Mouse heart 31 d after inject-
ing 105 undifferentiated ES cells. Hematoxylin and eosin staining of cross 
sections in this heart revealed intracardiac tumor distribution. (D) Periodic 
acid Schiff staining evidenced cartilagineous (closed arrows), squamous 
(red arrows), and glandular (open arrows) differentiation. (E) Combined 
desmin (red) and toluidine blue staining proved differentiated cartilage 
(closed arrows), mucous glandular (open arrows), and red-stained muscle 
tissue. Bars: (B and C) 250 μm; (D and E) 150 μm. JEM VOL. 203, October 2, 2006  2319
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Purity of puromycin-treated ES cell cultures
For transplantation purposes, and to avoid tumor develop-
ment, a very high purity of prediff  erentiated cardiomyocytes 
is absolutely required; therefore, we used a variety of diff  er-
ent technical approaches to quantitatively assess the purity of 
puromycin-treated cultures and the extent of contamination 
with undiff  erentiated ES cells.
RT-PCR analysis using Oct-4 as a “bona fi  de” marker 
of undiff  erentiated mouse ES cells (19) showed that after 
10 d of puromycin treatment no Oct-4 transcripts were de-
tected by PCR (Fig. 4 A). This was further corroborated 
with Trypan blue staining by which untreated EBs contained 
75% viable (Trypan blue−) noncardiac (EGFP−) cells (n = 
1462), whereas this fraction decreased to 0.7% (n = 884) 
  after 10 d of puromycin selection (not depicted). Finally, 
to defi  nitively assess the purity of drug-selected EBs, we 
counted the number of EGFP+ and α-actinin+ cardiomyo-
cytes versus noncardiomyocytes (Fig. 4 B). Consistent with 
previous results (9), only 1.8% of cells in the untreated EBs 
were cardiomyocytes (EGFP+ and α-actinin+; n = 1334; 
Fig. 4 C, left). After puromycin treatment for 10 d, 99.4% 
of the cells were cardiomyocytes, whereas only 0.6% of all 
nucleated cells were noncardiomyocytes (n = 168; Fig. 4 C, 
right). The identity of these puromycin-resistant noncardio-
myocytes was not determined.
We have also established a simple and sensitive assay to 
determine the minimal time of puromycin required to elimi-
nate all undiff  erentiated ES cells. The selected cardiomyo-
cytes were seeded on feeder cells, and the growth of ES cell 
colonies was monitored in the absence of puromycin. When 
cardiac clusters were treated with puromycin for at least 9–10 d, 
no colony growth was observed and, therefore, this purifi  ca-
tion protocol was used for transplantation experiments.
The potential damage of cardiomyocytes by our novel 
  lineage selection protocol was excluded with immunohisto-
chemistry where structural integrity and the typical cross striation 
were found (Fig. 4 B). Furthermore, puromycin-selected 
  cardiomyocytes displayed normal action potentials at early 
and late stages of development (Fig. 5 A). As reported earlier 
for ES cell–derived and mouse embryonic cardiomyocytes 
(9), a signifi  cant shortening of the action potential duration at 
90% repolarization (from 65.0 ± 8.1 ms in briefl  y puromycin 
exposed [n = 9] to 25.3 ± 4.9 ms in long puromycin exposed 
[n = 7]) and a signifi  cantly more negative maximal diastolic 
potential (−49.5 ± 2.1 mV in briefl  y exposed to −58.1 ± 
1.7 mV after long puromycin exposure) were clear indications 
that these cells were physiologically intact cardiomyocytes 
and diff   erentiated during cultivation (Fig. 5 B). Our data 
demonstrate that puromycin selection induces formation of 
high purity (>99%) of morphologically and physiologically 
intact cardiomyocytes.
Transplantation of puromycin-selected ES cell–derived 
cardiomyocytes into injured hearts of syngeneic mice
We next investigated the potential of purifi  ed ES cell–  derived 
cardiomyocytes for engraftment and repair of the injured 
myocardium. ES cell–derived cardiomyocytes (3 × 104–105) 
were transplanted 9–12 d after puromycin selection into in-
farcted hearts of syngeneic mice. Surprisingly, poor engraft-
ment of the transplanted cells was observed, as only 22% of 
Figure 3.  Puromycin-based selection and enrichment of ES 
cell–derived cardiomyocytes. (A) Scheme of the bicistronic vector 
(top). EGFP+ areas in EBs at day 9 (left) and fast selection after addi-
tion of 10 μg/ml puromycin (middle and right). (B) Puromycin treat-
ment induced a 6–10-fold increase in EGFP+ cells (triangles) compared 
with untreated EBs (circles). Data were obtained from four experi-
ments, and the cell number at day 16 was set for each experiment to 
100% for the puromycin group. (C) BrdU labeling (green) and anti-
EGFP staining (Cy3, red) in untreated (left) and puromycin-treated 
(3 d after selection; right) EBs. (D) Statistics of BrdU labeling in un-
treated (circles) and treated (triangles) EBs. The number of proliferat-
ing cells was calculated after 24 h of BrdU incubation at days 0, 3, or 
7 of puromycin selection. Data were obtained from two independent 
experiments. Bars: (A) 250 μm; (C) 50 μm.2320  TRANSPLANTATION OF BM CELLS AND ES CELL–DERIVED CARDIOMYOCYTES | Kolossov et al.
mice (n = 9) contained any detectable EGFP+ cells 3 wk after 
operation. We therefore reevaluated our earlier data in which 
embryonic heart–derived cells were found to stably engraft 
within the injured myocardium (17); analysis revealed that 
approximately half of the cells in embryonic hearts are car-
diomyocytes, whereas the remaining noncardiomyocytes are 
primarily fi  broblasts (20). We therefore determined whether 
fi  broblasts might play a facilitating role for cardiomyocytes by 
co-cultivating purifi  ed ES cell–derived cardiomyocytes with 
fi  broblasts. We found that purifi  ed cardiomyocytes did not 
adhere well to gelatin coated culture dishes and did not main-
tain their typical elongated shape of cardiomyocytes (Fig. 5 C, 
bottom). However, cardiomyocytes plated onto embryonic 
feeder cells maintained an elongated cell shape for weeks and 
even aligned with the fi  broblasts (Fig. 5 C, top). Microelec-
trode array (MEA) recordings of fi  eld potentials in these co-
cultures revealed synchronous signals from electrodes in 
contact with EGFP+ cardiomyocyte clusters over several 
weeks (n = 2; Fig. 5 D). These results suggest that formation 
of a functional syncytium occurs between cardiomyocytes 
and fi  broblasts.
Based on these fi  ndings, we analyzed the eff  ect of injecting 
equal numbers of puromycin-selected ES cell–derived cardio-
myocytes and syngeneic fi  broblasts into injured myocardium. 
This approach resulted in a substantial increase of cell engraft-
ment. Prominent EGFP fl  uorescence, a reliable parameter 
for engraftment, was detected in 68.3% of operated hearts 
(n = 60) up to 147 d (mean = 63 d) after cellular cardiomyo-
plasty (Fig. 6 A). Interestingly, the ratio of engraftment did not 
vary between middle (<100 d, 68.2%; n = 44) and long-term 
(>100 d, 68.7%; n = 16) transplantations, implying that graft 
rejection is not a prominent problem. Transplanted cardiomy-
ocytes were localized within the border zones of damaged 
  areas of the myocardium. In cryosections, an almost transmural 
distribution of the implanted cells could be observed (Fig. 6 B). 
The injected cells colocalized in clusters but could be clearly 
distinguished from the native cardiomyocytes because of their 
reduced size, distinct cell shape, and incomplete myofi  brils 
Figure 4.  Purity of puromycin-selected ES cell–derived cardio-
myocytes. (A) Oct-4 expression in undifferentiated ES cells (lane 1), 
beating EBs with EGFP+ areas plated for 9 d (lane 2), and EBs treated for 
10 d with puromycin (lane 3). (B) α-Actinin (Cy3, red) staining of puro-
mycin-selected EGFP+ cardiomyocytes (green); cell nuclei were stained 
with Hoechst dye (blue). (C) In 9-d-old EBs,  2% cardiomyocytes 
(EGFP+/α-actinin+; n = 1334, one representative experiment out of two; 
left graph) were found. After 10 d of puromycin selection, over 99% of 
cells were cardiomyocytes (n = 168; right graph). Bars: (B, top) 21 μm; 
(B, bottom) 12 μm.
Figure 5.  Characteristics of puromycin-selected ES cell–derived 
cardiomyocytes and interaction with fi  broblasts. (A) Action potentials 
in an isolated EGFP+ cardiomyocyte exposed for 16 d to puromycin. 
(B) Action potential duration at 90% repolarization (APD90; left y axis; 
P < 0.01) and maximal diastolic potential (MDP; right y axis; P < 0.01) at 
different time points of puromycin exposure (brief exposure [6–10 d], 
closed bars; long exposure [13–16 d], gray bars). (C) Morphology of 
EGFP+ cardiomyocytes after co-cultivation with embryonic fi  broblasts for 
6 d (top) and on gelatin-coated dishes for 6 d (bottom). (D) Co-culture of 
EGFP+ cardiomyocytes and embryonic fi  broblasts on an MEA for record-
ing fi  eld potentials (red traces). The image and the recordings were taken 
4 d after starting the co-cultivation. Bars: (C) 100 μm; (D) 400 μm.JEM VOL. 203, October 2, 2006  2321
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shortly after transplantation, strongly supporting the conclu-
sion that the EGFP+ cells did not result from fusion with na-
tive cardiomyocytes. In the long-term transplants, the ES 
cell–derived cardiomyocytes displayed elongated cell shapes 
and distinct cross-striation, proving that the engrafted EGFP+ 
cells further diff  erentiate after the transplantation (Fig. 6 C). 
We next examined the basis for intercellular coupling by ana-
lyzing gap junction formation based on connexin 43 staining. 
As depicted in Fig. 6 D, gap junctions were detected between 
the transplanted cardiomyocytes.
Although no tumors developed in 95% (n = 60) of trans-
planted mouse hearts, three hearts harvested 45, 90, and 91 d 
after transplantation did reveal tumors, the latter two evolved 
from the same preparation of cells (Fig. 6 E). Histological 
analysis of two of these hearts revealed mesenchymal tumors 
closely resembling the pleomorphic variant of malignant 
  fi  brous histiocytoma and not teratomas (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20061469/DC1). 
Thus, our transplantation data indicate that undiff  erentiated 
ES cells are completely eliminated by our lineage selection 
method, leading to an abolishment of teratoma formation 
after transplantation.
Improvement of LVF after transplantation of puromycin-
selected ES cell–derived cardiomyocytes and of contractility 
after in vitro transplantation
To assess whether transplantation of ES cell–derived cardio-
myocytes and fi  broblasts resulted in enhancement of func-
tion in infarcted hearts, hemodynamics was determined 3–4 
wk after surgery. Pressure-volume loops (Fig. 7 A) revealed 
a signifi  cant enhancement of LVEF (P < 0.01; 51.6 ± 6.2% 
vs. 36.3 ± 11.1%) and reduction of the enddiastolic volume 
(P < 0.05; 46.5 ± 6.6 μl vs. 58.5 ± 18.4 μl) in mice with 
cardiomyoplasty (n = 12) versus sham injection (n = 11; 
Fig. 7 B and Table S1). As a further control, we transplanted 
105 EGFP+ fi  broblasts and analyzed LVF after 3–4 wk. In 
contrast to ES cell–derived cardiomyocytes, no diff  erence in 
LVEF (53.6 ± 7.1% vs. 50.3 ± 6.1%; Fig. 7 D and Table S1) 
Figure 6.  Engraftment of puromycin-selected ES cell–derived 
  cardiomyocytes into injured hearts of syngeneic mice, including 
statistics of tumor incidence. (A) Engraftment of EGFP+ cardiomyo-
cytes in an infarcted heart 40 d after injection of 105 ES cell–derived car-
diomyocytes and 105 embryonic fi  broblasts. (B) Cross section of a heart 
60 d after injecting 8 × 104 ES cell–derived cardiomyocytes and 8 × 104 
embryonic fi  broblasts. (C) α-Actinin staining (middle) of a transplanted, 
engrafted EGFP+ (left) ES cell–derived cardiomyocyte (overlay of the two 
images, right). (D) Immunostaining for connexin 43 (Cy3, red) showing 
gap junctions between the transplanted cardiomyocytes (arrows) and 
nuclear staining (blue) with Hoechst dye. (E) Statistics of tumor incidence. 
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and enddiastolic volume (60.5 ± 12.5 μl vs. 57.0 ± 12.2 μl) 
between the fi  broblast (n = 6) and sham-injected (n = 6) 
mice was observed, although histological analysis proved 
good engraftment of the EGFP+ fi   broblasts (Fig. 7 C). 
We also tested the effi     cacy of transplanting EGFP+ ske-
letal myoblasts (105, n = 5). These cells were found to en-
graft well into the lesion (Fig. S2, A and B, available at 
http://www.jem.org/cgi/content/full/jem.20061469/DC1), 
and LVEF was signifi  cantly enhanced (P < 0.01; 60.6 ± 
2.8% [n = 5] vs. 48.0 ± 5.7% [n = 5]; Fig. S2 C and Table 
S1). Because skeletal myoblasts are proven to not integrate 
functionally into the myocardium, we presume that the 
  improvement of heart function was mainly caused by the 
signifi  cant   reduction of left enddiastolic volume (P < 0.05; 
33.2 ± 9.2 μl vs. 51 ± 8.7 μl).
Recent work (6) suggests that transplanted cells may act 
mainly via paracrine mechanisms. To determine whether the 
enhancement of LVF of ES cell–derived cardiomyocytes in 
vivo may be caused by active contribution rather than exclu-
sively paracrine mechanisms, we assessed whether purifi  ed ES 
cell–derived cardiomyocytes generate force and transfer this 
to the surrounding tissue. For this purpose we established an 
“in vitro transplantation” model in which the purifi  ed ES 
cell–derived cardiomyocytes were transferred to ischemic 
ventricular slices (see scheme in Fig. 8 A) and measured iso-
metric force generation 1–2 wk after co-culture. Although 
ventricular slices without ES cells neither produced sponta-
neously nor after electrical stimulation any force (n = 4; Fig. 
8 B,D), ES cell–derived cardiomyocytes generated a force of 
6.1 ± 0.8 μN (n = 5) at a spontaneous rate of 2.6 ± 0.3 Hz 
and an even higher force of 8.6 ± 1.7 μN at a stimulation 
frequency of 3 ± 0.4 Hz (Fig. 8, C and D).
Hence, functional studies demonstrate that transplanta-
tion of puromycin-selected ES cell–derived cardiomyocytes 
results in engraftment, with clear augmentation of LVF in 
vivo and enhanced force of contraction in vitro.
DISCUSSION
The aim of this paper was to identify the most promising cell 
type for treatment of the infarcted heart. The investigation 
was largely motivated by the controversy surrounding the 
effi   cacy of adult BM cells and ES cells for cardiomyoplasty 
(for review see references 1, 2). Although BM cells are easily 
accessible and allow autologous transplantations, it is still un-
clear and controversial whether these cells can improve de-
fective heart function and whether this treatment is entirely 
safe. In fact, studies in animals suggest that cytokine treat-
ment may carry the risk of accelerated restenosis of coronary 
arteries (21), and direct injection of BM cells may carry the 
risk of extended calcifi  cations (22).
ES cells represent an ideal stem cell source for ex vivo 
generation of cardiomyocytes; however, studies are still miss-
ing in which their long-term, teratoma/tumor-free engraft-
ment and enhancement of LVF are carefully evaluated. 
To address this critical topic, we used a highly reproducible 
infarction model and assessed the fate and functional rele-
vance of transplanting ES cell–derived cardiomyocytes and 
compared this with the eff  ect of transplanted BM cells, as 
Figure 7.  LVEF measurements after transplantation of ES 
cell–derived cardiomyocytes/fi  broblasts or only fi  broblasts. (A) Rep-
resentative pressure-volume loops 3–4 wk after injecting 105 ES cell–
derived cardiomyocytes and fi  broblasts (left) or vehicle (right) into 
infarcted hearts. (B) Statistics of LVEF (P < 0.01). (C) Sirius red staining 
of injured myocardium (left) and engraftment of EGFP+ fi  broblasts into 
the infarcted heart (right) after injection of 105 embryonic fi  broblasts. 
(D) Statistics of LVEF after injecting fi  broblasts or vehicle (P = 0.42). 
LVEF in B (SV129) and D (C57BL/6) are normalized to data from respec-
tive congeneic WT mice. Original data are listed in Table S1. Note the 
difference in LVEF between the two mouse strains. Bars: (C, left) 250 μm; 
(C, right) 270 μm.JEM VOL. 203, October 2, 2006  2323
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well as fi  broblasts and noncardiomyocytes. To avoid immuno-
logical interference and to be able to determine the tumori-
genic risk of highly purifi  ed ES cell–derived cardiomyocytes, 
a syngeneic transplantation model was chosen. Thus, in case 
our purifi  cation approach of ES cell–derived cardiomyocytes 
turned out to be safe, it would be even safer in the clinically 
more relevant allogeneic setting (14). Nevertheless, the   recent 
identifi  cation of pluripotent cells in testicles of adult mice re-
vealed a therapeutically relevant new autologous ES cell–like 
source (23). Moreover, ongoing experiments on nuclear 
cloning and nuclear cloning–derived ES cells will soon also 
bring this approach closer to clinical application (24).
Our experimental results demonstrate that neither direct 
injection nor cytokine-induced mobilization of BM cells 
  reduced scar formation and/or enhanced LVF 3–4 wk after 
injury. This time point was chosen to allow the engraftment 
and further diff   erentiation of BM progenitors. Consistent 
with our earlier fi  ndings (5), we could not detect transdiff  er-
entiation of BM cells into cardiomyocytes using immunohis-
tochemistry. To date the fate of transplanted BM cells has 
only been investigated with this approach, and we therefore 
have also performed single cell analysis using the patch-clamp 
technique whereby even the functional diff  erentiation of BM 
cells into early embryonic cardiomyocytes (>E8.5) was ex-
cluded. We also could not detect, in contrast to earlier studies 
in mice (3) and human transplanted hearts (25), the contribu-
tion of BM cells to endothelial or smooth muscle cells of ves-
sels in infarcted hearts. Our fi   ndings are corroborated by 
measurements of hemodynamics, where neither direct injec-
tion nor mobilization of BM cells had a positive impact in 
Figure 8.  In vitro transplantation experiments. (A) Protocol of in 
vitro transplantation experiments. (B) Measurements of force generation in 
a stimulated (downward defl  ections on top bar) control slice without trans-
planted cells (note the different scaling). (C) Slices with ES cell–derived 
cardiomyocytes generate force spontaneously (left) and after electrical 
stimulation (6 Hz, right). (D) Statistics of spontaneous and stimulated force 
generation in slices without (control) and with ES cell–derived cardiomyo-
cytes (P < 0.001).2324  TRANSPLANTATION OF BM CELLS AND ES CELL–DERIVED CARDIOMYOCYTES | Kolossov et al.
contrast to earlier reports (3, 26). Thus, in a large number of 
animals, our studies exclude prominent neogenesis of cardio-
myocytes and vessels from BM cells transplanted into in-
farcted hearts. Importantly, our results concur with recent 
clinical trials in which neither application of BM cells into af-
fected coronary arteries (27) nor BM mobilization (28) had 
benefi  cial eff  ects on LVF.
In clear contrast to the BM cells, highly purifi  ed  ES 
cell–derived cardiomyocytes were found to long-term en-
graft (4–5 mo) and to clearly improve LVF. Because para-
crine eff  ects have been claimed to be potentially responsible 
for the benefi  cial eff  ects observed after cellular cardiomyo-
plasty (6), we addressed this using an in vitro transplantation 
model. The experiments clearly proved that the ES cell–
  derived cardiomyocytes generate force and transfer this to the 
surrounding tissue. Thus, if massive engraftment of ES cell–
derived cardiomyocytes into the infarcted myocardium is 
achieved, a strong functional improvement can be obtained.
In accordance with earlier work (29), we found that skel-
etal myoblasts engraft well into the infarcted myocardium 
and augment LVF. Because these cells are known to not 
couple electrically with the native myocardium (30) because 
of a lack of connexin 43 expression (31), their benefi  cial 
  eff  ect is most likely caused by stabilization of the scar region, 
resulting in a considerable reduction of the enddiastolic 
  volume. However, their therapeutic use does not appear 
promising, as experimental data in vitro (32) and in vivo (33) 
indicate that skeletal myoblasts can induce ventricular ar-
rhythmias via reentry; similar events have been also observed 
in the clinical trials (29).
The major challenge for clinical development of ES cell–
derived cardiomyocytes has been to develop safe and effi   cient 
methods for their enrichment in vitro, measures to ensure 
their long-term engraftment, and, most importantly, avoid-
ance of tumorigenicity caused by contaminating ES cells. 
This prompted us to develop a cardiac lineage–specifi  c selec-
tion to purify ES cell–derived cardiomyocytes. Unexpect-
edly, we discovered that elimination of noncardiomyocytes 
was accompanied by a burst of proliferation, which produced 
6–10 times more cardiomyocytes. At this time we can only 
speculate about the underlying mechanisms and assume that 
noncardiomyocytes and/or undiff  erentiated ES cells normally 
produce factors that inhibit the proliferation of diff  erentiating 
cardiomyocytes within the EBs.
Tumors are currently considered the major hurdle for ES 
cell–derived transplantation, as very few undiff  erentiated ES 
cells suffi   ce for teratoma growth in the heart (this study), the 
brain (14), and the kidney (15). We have succeeded in estab-
lishing a highly purifi  ed ES cell–derived cardiomyocyte prep-
aration (>99%) and show, to our knowledge for the fi  rst 
time, in a large number of animals that teratoma formation 
after ES cell–based transplantation can be completely avoided, 
even long-term (4–5 mo), in syngeneic recipients. In fact, 
only 3 out of 60 hearts developed tumors, of which 2 were 
not teratomas but rather poorly diff  erentiated mesenchymal 
tumors, and these most likely arose from the co-transplanted 
embryonic fi   broblasts (the malignant fi  brous  histiocytoma 
looks predominantly fi  broblast-like) (34). Our data also dem-
onstrate that studies with much larger cohorts and longer 
  follow-up periods than reported earlier (10, 13) are needed
to assess the risk of tumor formation after transplantation of 
ES cell–derived cells.
Cellular replacement approaches in diff  erent tissues have 
proven to be of limited effi   cacy, as the transplanted cells are 
subject to a high rate of death within hours after transplanta-
tion (35). To date, the mechanisms responsible for this have 
been unclear but do not appear to be exclusively immune 
mediated, as similar rates of cell death are observed in the 
presence of immunosuppressants (20). Our experimental data 
imply that the extracellular matrix plays an important permis-
sive role in cell survival and viability (36). This likely refl  ects 
the fact that fi  broblasts provide extracellular matrix support 
for developing cardiomyocytes but also possibly critical 
growth factors and cytokines, as recently reported for the in 
vitro diff  erentiation of cardiac progenitor cells into cardio-
myocytes (37).
In conclusion, we show that ES cell–derived cardiomy-
ocytes can be highly purifi  ed, enriched, and do long-term 
engraft in the infarcted heart without teratoma formation. 
Most importantly, our comparative study demonstrates 
that ES cell–derived cardiomyocytes are the most suitable 
candidates for cellular cardiomyoplasty, as these cells en-
hance, in contrast to BM cells, the contractile function of 
the   lesioned myocardium.
MATERIALS AND METHODS
All animal experiments were approved by the local animal care committees 
of the Universities of Bonn, Cologne, and Lund.
Harvesting of BM cells and mobilization in reconstituted mice.
BM cells were obtained by fl   ushing femur and tibia with PBS using a 
27-gauge needle. Mobilization of hematopoietic stem cells was performed as 
described previously (5). In brief, lethally irradiated mice were transplanted 
with congeneic 106 EGFP+ (under control of the chicken β-actin promoter) 
whole BM cells, and multilineage hematopoietic reconstitution was evalu-
ated at week 5 in peripheral blood. For mobilization, fi  ve daily injections of 
5 μg of recombinant human Flt-3 ligand and 5 μg of recombinant mouse 
granulocyte/macrophage colony-stimulating factor were applied, starting 1 h 
after myocardial infarction.
Generation of transgenic ES cell clones. The pIRES2-EGFP vector 
(CLONTECH Laboratories, Inc.) was truncated via excision of the CMV-
IE promoter by AseI-NheI and religated. The α-MHC promoter (5.5-kb 
BamHI–Sal I fragment) of the α-MHC–pBK plasmid (provided by J. Rob-
bins, University of Cincinnati, Cincinnati, OH) and the PuromycinR (Pac) 
cassette (HindIII-ClaI fragment) of the pCre-Pac vector were inserted into the 
multiple cloning site of the truncated pIRES2-EGFP vector. The α-MHC–
Pac–IRES–EGFP vector was linearized by SacI restrictase, and 40 μg was 
used for transfection. Electroporation, G418 (Neomycin) selection, and 
propagation of clones was performed as reported previously (18).
ES cell diff  erentiation and selection of cardiomyocytes. For ES cell 
diff  erentiation, IMDM high glucose medium was supplemented with 20% 
FCS (Invitrogen) in the absence of leukemia inhibitory factor. The hanging 
drop (18) and the mass culture protocol (see the following sentence) were 
used for cardiomyocyte diff  erentiation from ES cells. For the mass culture 
protocol, ES cells were suspended in 3 ml of diff  erentiation medium (day 0) JEM VOL. 203, October 2, 2006  2325
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and placed on a horizontal shaker for 2 d to allow formation of EBs. These 
were diluted to a density of 100–200 EBs/10 ml and kept in diff  erentiation 
medium. EGFP+ areas in EBs were initially detected after 7–9 d of culture. 
10 μg/ml puromycin was added on days 9–10, and the medium was subse-
quently changed every 2–3 d. After 7–10 d of puromycin selection, EBs 
were isolated as previously reported (18).
Preparation of skeletal myoblasts and fi  broblasts. EGFP+ fi  broblasts 
were prepared from transgenic C57BL/6 (under control of the chicken 
β-actin promoter) embryos (E14.5–15.5) using standard protocols. EGFP+ 
skeletal myoblasts were obtained from hindlimb muscles of transgenic 
C57BL/6 (under control of the cardiac-α-actin promoter [38]) embryos 
(E18.5) using standard protocols.
Proliferation and viability assays. Cardiomyocyte numbers were deter-
mined at diff  erent time points in puromycin-treated and untreated EBs by 
digesting 100 EBs and counting EGFP+ cells. For BrdU labeling, the BrdU 
kit (Roche) was used in accordance with the manufacturer’s protocol. In 
brief, EBs were incubated with BrdU for 24 h on days 0 or 3 or 7 of puro-
mycin treatment, dissociated, and, after 2 more days, fi  xed and stained with 
anti-BrdU antibody. Because EGFP fl  uorescence is quenched by ethanol 
  fi  xation, cells were immunostained using anti-GFP–rabbit polyclonal IgG 
(Santa Cruz Biotechnology, Inc.) and a Cy3-conjugated secondary antibody. 
Saturating BrdU labeling of EBs was achieved using incubation periods of 72 h. 
The labeling index was calculated as the ratio of the BrdU+/EGFP+/Cy3+ of 
total EGFP+/Cy3+ cells. To assess cardiomyocyte proliferation, estimates of 
the proliferative pool and cell numbers during the fi  rst 3 d of puromycin 
treatment were introduced in the following formula: TC = Txln2/lnN-lnN0 
(where TC is the cell cycle length, T is the time after beginning of puromycin 
treatment [72 h], N0 is the cell number at the beginning of puromycin 
  treatment, and N is the cell number after 72 h of puromycin treatment). Try-
pan blue (0.2%; Invitrogen) exclusion was used to assess the viability of de-
veloping cells isolated from EBs. To reveal the number of cardiomyocytes 
after dissociation of EBs, α-actinin (Sigma-Aldrich) immunostaining was per-
formed in combination with Hoechst 33342 (Sigma-Aldrich).
RNA extraction and RT-PCR. Total RNA was prepared from 3 × 106 un-
diff  erentiated ES cells and 100–200 control or puromycin-treated (10 d) EBs. 
RNA was prepared as previously described (39). After the standard protocol 
(QIAGEN), 2 μl of fi  rst-strand cDNA was used in a 20-μl PCR reaction to 
detect the expression of Oct-4 (forward primer, 5′-A  G  G  A  A  G  C  C  G  A  C  A  A-
C  A  A  T  G  A  G  -3′; reverse primer, 5′-G  A  G  C  A  G  T  G  A  C  G  G  G  A  A  C  A  G  A  G  -3′) 
and GAPDH (forward primer, 5′-T  G  T  C  A  G  C  A  A  T  G  C  A  T  C  C  T  G  C  A  -3′; 
reverse primer, 5′-C  C  G  T  T  C  A  G  C  T  C  T  G  G  G  A  T  G  A  C  -3′). Samples with-
out addition of reverse transcriptase served as negative controls. The PCR 
products were separated on 2% agarose by electrophoresis and documented 
by ethidium bromide staining on an UV transilluminator.
Myocardial infarction, transplantation of cells, and left ventricular 
catheterization. 12-wk-old male mice (strain SV 129 Ico/Pas for ES cells 
and C57BL/6 for all other cell types) were anesthetized, and a large cryole-
sion (4-mm diameter) or LCA ligation were generated as previously de-
scribed (17). 3 × 106 EGFP transgenic (β-actin promoter) unfractioned 
BM cells; 3 × 104–105 ES cell–derived cardiomyocytes and equal numbers 
of syngeneic embryonic fi  broblasts; 105 EGFP transgenic (human α-actin 
promoter) embryonic (E18.5) skeletal myoblasts; or 105 EGFP transgenic 
(β-actin promoter) fi  broblasts suspended in 5 μl of medium were injected 
into the center and border zones of the lesion. Control animals were injected 
with vehicle only.
3–4 wk after transplantation, LVEF was assessed on anesthetized mice 
  using the Millar ARIA 1 system (Millar); the investigators were blinded. The 
LVEF was normalized with the data obtained from SV 129 Ico/Pas (n = 7) or 
C57BL/6 (n = 6) control mice of the same age and sex, and these data are 
shown in the Fig. 1, O and P; Fig. 7, B and D; and Fig. S2. The original data 
of LVF are listed in Table S1.
Electrophysiology and extracellular recordings. Hearts of cryoinjured 
and mobilized mice were dissociated using a Langendorff   system (n = 4) 
(20), and patch clamp recordings were performed in the whole cell confi  gu-
ration at room temperature. Voltage ramps (−80 to +50 mV, 250 ms) were 
used to identify inward and outward currents, and slow depolarizing current 
ramps (from a current corresponding to −80 mV, 10 s) were used to evoke 
action potentials.
For experiments on ES cell–derived cardiomyocytes, the EBs were 
enzymatically dissociated, and electrophysiological recordings were per-
formed 36–48 h later (9). Cardiomyocytes isolated after 6–10 d of puromy-
cin treatment were considered to be briefl   y exposed, whereas a long 
exposure lasted 13–16 d.
For extracellular recordings, cardiomyocytes (2 × 105 cells) and 
  mitotically inactivated embryonic fi  broblasts were seeded in the culture 
area of an MEA (Multi Channel Systems) (40). Spontaneous electrical 
  activity was recorded with software (MC Rack; Multi Channel Systems) 
(41). Data were recorded simultaneously from 59 channels with a sampling 
frequency of 4 kHz.
In vitro transplantation using ES cell–derived cardiomyocytes. 
  Ventricular slices were generated, as described previously (42), from neonatal 
mice (3–4 d after birth) of the strain SV129. The scheme of the co-culture 
of ventricular slices and puromycin-selected ES cell–derived cardiomyocytes 
is shown in Fig. 8 A. In brief, slices were transferred into a hypoxia chamber 
and exposed to a nominally O2-free condition and a Tyrode’s solution where 
glucose was replaced by equimolar concentrations of 2-deoxy-glucose for 
4.5 h. The slices were transferred to IMDM supplemented with 20% FCS 
and stored in the incubator (37°C, 5% CO2) until co-culturing. Clusters of 
beating areas (24–30) of mouse ES cell–derived cardiomyocytes and slices 
were transferred into a custom-made well and co-cultured for 1–2 wk. The 
preparation was mounted on an isometric force transducer (Scientifi  c Instru-
ments) in IMDM without FCS, and the maximal force development (Lmax) 
was determined. The control ischemic slices without ES cell–derived cardio-
myocytes did not produce force spontaneously and on stimulation (Fig. 8 B). 
Contractions were recorded from spontaneously beating and electrically 
stimulated preparations containing ES cell–derived cardiomyocytes; stimula-
tion frequencies were only a little over (≤27%) the spontaneous rate. Field 
stimulation was performed with silver electrodes (0.5–10 Hz, 5–15 V; stim-
ulus pulse duration, 5 ms) connected to a custom-made stimulator. Electrical 
stimuli and analogue signals from the force transducer (KG7A; range, 
0–5 mN; resolution, 0.2 μN; resonance frequency, 250–300 Hz) were 
  amplifi  ed with a bridge amplifi  er (BAM7C; Scientifi  c Instruments), and 
  analogue signals were transferred to an A/D board and recorded, as well as 
analyzed, using software (DasyLab version 7.0; National Instruments).
Histology and immunohistochemistry. Hearts were harvested, and 
  engraftment of EGFP+ cells was documented with a fl  uorescence micro-
scope (SMZ 1000; Nikon). Histology/immunohistochemistry was per-
formed as described previously (20). In brief, hearts were fi  xated in situ and 
cryopreserved for immunostainings. Serial sections were taken at 200–400 μm 
intervals to cover the whole infarcted area. Labeling was done using primary 
antibodies against α-sarcomeric actinin (1:400; Sigma-Aldrich), ASMAC 
(1:400; Sigma-Aldrich), CD45 (1:400; Neomarkers), PECAM (1:400; BD 
Biosciences), von Willebrand factor (1:200; Chemicon International), and 
connexin 43 (1:400; Bio Trend). Primary antibodies were visualized by sec-
ondary antibodies conjugated to Cy3 and Cy5 (1:400; Dianova), and nuclei 
were stained with Hoechst 33342 (Sigma-Aldrich).
For analysis of cardiac diff  erentiation, 27 sections of 6 hearts were inves-
tigated, and contribution to vessels was assessed in 69 sections of 10 hearts. 
Immunostainings were documented with an inverted microscope (Axiovert 
200; Carl Zeiss MicroImaging, Inc.) equipped with a slider module 
  (ApoTome; Carl Zeiss MicroImaging, Inc.).
Statistical analysis. Statistical signifi  cance was determined using the Stu-
dent’s t test after confi  rmation of normal distribution. P < 0.05 was consid-
ered signifi  cant. All errors are SD, with the exception of the electrophysiological 2326  TRANSPLANTATION OF BM CELLS AND ES CELL–DERIVED CARDIOMYOCYTES | Kolossov et al.
and contraction parameters in Fig. 1, L–N; Fig. 5 B; and Fig. 8 D, which are 
shown as SEM.
Online supplemental material. Table S1 measured and normalized 
(WT mice) values of LVEF. Video 1 shows long-term observation of a trans-
genic EB before and during puromycin selection. Fig. S1 depicts formation 
of malignant fi  brous histiocytoma 90 d after transplantation of puromycin-
  selected ES cell–derived cardiomyocytes. Fig. S2 shows engraftment and 
LEVF after transplantation of skeletal myoblasts. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20061469/DC1.
We thank C. Böttinger, M. Czechowski, F. Holst, P. Metzger, and L. Rochlin for 
cell culture work; C. Sekhar for help with the vector construct; E. Ratering for 
cell preparation; Dr. Liu and A. Koester for help with histological analysis and 
immunohistochemistry; and Dr. B. Freedman for carefully reading the manuscript.
This study was supported by grants from the Deutsche 
Forschungsgemeinschaft (273-2/3 to W. Roell and B.K. Fleischmann); the Köln 
Fortune Program (157/2003 to F. Pillekamp); the Swedish Research Council and the 
Swedish Heart and Lung Foundation (to S.E. Jacobsen and S. Jovinge); and the 
scientifi  c exchange program North Rhine Westphalia–Sweden.
The authors have no confl  icting fi  nancial interests.
Submitted: 11 July 2006
Accepted: 10 August 2006
REFERENCES
 1. Lafl  amme, M.A., and C.E. Murry. 2005. Regenerating the heart. Nat. 
Biotechnol. 23:845–856.
 2. Murry, C.E., L.J. Field, and P. Menasche. 2005. Cell-based cardiac 
  repair: refl  ections at the 10-year point. Circulation. 112:3174–3183.
 3. Orlic, D., J. Kajstura, S. Chimenti, I. Jakoniuk, S.M. Anderson, B. Li, 
J. Pickel, R. McKay, B. Nadal-Ginard, D.M. Bodine, et al. 2001. Bone 
marrow cells regenerate infarcted myocardium. Nature. 410:701–705.
 4. Murry, C.E., M.H. Soonpaa, H. Reinecke, H. Nakajima, H.O. 
Nakajima, M. Rubart, K.B. Pasumarthi, J.I. Virag, S.H. Bartelmez, V. 
Poppa, et al. 2004. Haematopoietic stem cells do not transdiff  erentiate 
into cardiac myocytes in myocardial infarcts. Nature. 428:664–668.
 5. Nygren, J.M., S. Jovinge, M. Breitbach, P. Sawen, W. Roll, J. 
Hescheler, J. Taneera, B.K. Fleischmann, and S.E. Jacobsen. 2004. 
Bone marrow-derived hematopoietic cells generate cardiomyocytes 
at a low frequency through cell fusion, but not transdiff  erentiation. Nat. 
Med. 10:494–501.
 6. Gnecchi, M., H. He, O.D. Liang, L.G. Melo, F. Morello, H. Mu, 
N. Noiseux, L. Zhang, R.E. Pratt, J.S. Ingwall, and V.J. Dzau. 2005. 
Paracrine action accounts for marked protection of ischemic heart by 
Akt-modifi  ed mesenchymal stem cells. Nat. Med. 11:367–368.
 7. Xiang, G., M.D. Schuster, T. Seki, A.A. Kocher, S. Eshghi, A. Boyle, 
and S. Itescu. 2004. Down-regulation of plasminogen activator inhibi-
tor 1 expression promotes myocardial neovascularization by bone mar-
row progenitors. J. Exp. Med. 200:1657–1666.
 8. Odorico, J.S., D.S. Kaufman, and J.A. Thomson. 2001. Multilineage 
diff   erentiation from human embryonic stem cell lines. Stem Cells. 
19:193–204.
 9. Kolossov, E., Z. Lu, I. Drobinskaya, N. Gassanov, Y. Duan, H. Sauer, 
O. Manzke, W. Bloch, H. Bohlen, J. Hescheler, and B.K. Fleischmann. 
2005. Identifi  cation and characterization of embryonic stem cell-
derived pacemaker and atrial cardiomyocytes. FASEB J. 19:577–579.
10.  Klug, M.G., M.H. Soonpaa, G.Y. Koh, and L.J. Field. 1996. Genetically 
selected cardiomyocytes from diff  erentiating embryonic stem cells form 
stable intracardiac grafts. J. Clin. Invest. 98:216–224.
11.  Zandstra, P.W., C. Bauwens, T. Yin, Q. Liu, H. Schiller, R. Zweigerdt, 
K.B. Pasumarthi, and L.J. Field. 2003. Scalable production of embry-
onic stem cell-derived cardiomyocytes. Tissue Eng. 9:767–778.
12. Behfar, A., L.V. Zingman, D.M. Hodgson, J.M. Rauzier, G.C. Kane, 
A. Terzic, and M. Puceat. 2002. Stem cell diff  erentiation requires a 
paracrine pathway in the heart. FASEB J. 16:1558–1566.
13. Menard, C., A.A. Hagege, O. Agbulut, M. Barro, M.C. Morichetti, 
C. Brasselet, A. Bel, E. Messas, A. Bissery, P. Bruneval, et al. 2005. 
Transplantation of cardiac-committed mouse embryonic stem cells to in-
farcted sheep myocardium: a preclinical study. Lancet. 366:1005–1012.
14. Erdo, F., C. Buhrle, J. Blunk, M. Hoehn, Y. Xia, B. Fleischmann, 
M. Focking, E. Kustermann, E. Kolossov, J. Hescheler, et al. 2003. 
Host-dependent tumorigenesis of embryonic stem cell transplantation 
in experimental stroke. J. Cereb. Blood Flow Metab. 23:780–785.
15. Lawrenz, B., H. Schiller, E. Willbold, M. Ruediger, A. Muhs, and 
S. Esser. 2004. Highly sensitive biosafety model for stem-cell-derived 
grafts. Cytotherapy. 6:212–222.
16. Lafl  amme, M.A., J. Gold, C. Xu, M. Hassanipour, E. Rosler, S. Police, 
V. Muskheli, and C.E. Murry. 2005. Formation of human myocar-
dium in the rat heart from human embryonic stem cells. Am. J. Pathol. 
167:663–671.
17.  Roell, W., Y. Fan, Y. Xia, E. Stoecker, P. Sasse, E. Kolossov, W. Bloch, 
H. Metzner, C. Schmitz, K. Addicks, et al. 2002. Cellular cardiomyo-
plasty in a transgenic mouse model. Transplantation. 73:462–465.
18. Kolossov, E., B.K. Fleischmann, Q. Liu, W. Bloch, S. Viatchenko-
Karpinski, O. Manzke, G.J. Ji, H. Bohlen, K. Addicks, and J. Hescheler. 
1998. Functional characteristics of ES cell–derived cardiac precursor 
cells identifi  ed by tissue-specifi  c expression of the green fl  uorescent pro-
tein. J. Cell Biol. 143:2045–2056.
19.  Nichols, J., B. Zevnik, K. Anastassiadis, H. Niwa, D. Klewe-Nebenius, 
I. Chambers, H. Scholer, and A. Smith. 1998. Formation of pluripotent 
stem cells in the mammalian embryo depends on the POU transcription 
factor Oct4. Cell. 95:379–391.
20. Roell, W., Z.J. Lu, W. Bloch, S. Siedner, K. Tiemann, Y. Xia, E. 
Stoecker, M. Fleischmann, H. Bohlen, R. Stehle, et al. 2002. Cellular 
cardiomyoplasty improves survival after myocardial injury. Circulation. 
105:2435–2441.
21. Kang, H.J., H.S. Kim, S.Y. Zhang, K.W. Park, H.J. Cho, B.K. Koo, 
Y.J. Kim, L.D. Soo, D.W. Sohn, K.S. Han, et al. 2004. Eff  ects of intra-
coronary infusion of peripheral blood stem-cells mobilised with granu-
locyte-colony stimulating factor on left ventricular systolic function and 
restenosis after coronary stenting in myocardial infarction: the MAGIC 
cell randomised clinical trial. Lancet. 363:751–756.
22. Yoon, Y.S., J.S. Park, T. Tkebuchava, C. Luedeman, and D.W. 
Losordo. 2004. Unexpected severe calcifi   cation after transplanta-
tion of bone marrow cells in acute myocardial infarction. Circulation. 
109:3154–3157.
23.  Guan, K., K. Nayernia, L.S. Maier, S. Wagner, R. Dressel, J.H. Lee, J. Nolte, 
F. Wolf, M. Li, W. Engel, and G. Hasenfuss. 2006. Pluripotency of sper-
matogonial stem cells from adult mouse testis. Nature. 440:1199–1203.
24. Brambrink, T., K. Hochedlinger, G. Bell, and R. Jaenisch. 2006. ES 
cells derived from cloned and fertilized blastocysts are transcription-
ally and functionally indistinguishable. Proc. Natl. Acad. Sci. USA. 
103:933–938.
25. Minami, E., M.A. Lafl   amme, J.E. Saffi     tz, and C.E. Murry. 2005. 
Extracardiac progenitor cells repopulate most major cell types in the 
transplanted human heart. Circulation. 112:2951–2958.
26.  Orlic, D., J. Kajstura, S. Chimenti, F. Limana, I. Jakoniuk, F. Quaini, B. 
Nadal-Ginard, D.M. Bodine, A. Leri, and P. Anversa. 2001. Mobilized 
bone marrow cells repair the infarcted heart, improving function and 
survival. Proc. Natl. Acad. Sci. USA. 98:10344–10349.
27. Janssens, S., C. Dubois, J. Bogaert, K. Theunissen, C. Deroose, W. 
Desmet, M. Kalantzi, L. Herbots, P. Sinnaeve, J. Dens, et al. 2006. 
Autologous bone marrow-derived stem-cell transfer in patients with 
ST-segment elevation myocardial infarction: double-blind, randomised 
controlled trial. Lancet. 367:113–121.
28.  Zohlnhofer, D., I. Ott, J. Mehilli, K. Schomig, F. Michalk, T. Ibrahim, 
G. Meisetschlager, J. von Wedel, H. Bollwein, M. Seyfarth, et al. 2006. 
Stem cell mobilization by granulocyte colony-stimulating factor in pa-
tients with acute myocardial infarction: a randomized controlled trial. 
JAMA. 295:1003–1010.
29. Menasche, P., A.A. Hagege, J.T. Vilquin, M. Desnos, E. Abergel, B. 
Pouzet, A. Bel, S. Sarateanu, M. Scorsin, K. Schwartz, et al. 2003. 
Autologous skeletal myoblast transplantation for severe postinfarction 
left ventricular dysfunction. J. Am. Coll. Cardiol. 41:1078–1083.
30. Leobon, B., I. Garcin, P. Menasche, J.T. Vilquin, E. Audinat, and S. 
Charpak. 2003. Myoblasts transplanted into rat infarcted myocardium JEM VOL. 203, October 2, 2006  2327
ARTICLE
are functionally isolated from their host. Proc. Natl. Acad. Sci. USA. 
100:7808–7811.
31. Reinecke, H., V. Poppa, and C.E. Murry. 2002. Skeletal muscle stem 
cells do not transdiff  erentiate into cardiomyocytes after cardiac grafting. 
J. Mol. Cell. Cardiol. 34:241–249.
32. Abraham, M.R., C.A. Henrikson, L. Tung, M.G. Chang, M. Aon, T. 
Xue, R.A. Li, B. O’Rourke, and E. Marban. 2005. Antiarrhythmic 
engineering of skeletal myoblasts for cardiac transplantation. Circ. Res. 
97:159–167.
33. Fernandes, S., J.C. Amirault, G. Lande, J.M. Nguyen, V. Forest, O. 
Bignolais, G. Lamirault, D. Heudes, J.L. Orsonneau, M.F. Heymann, 
et al. 2006. Autologous myoblast transplantation after myocardial infarc-
tion increases the inducibility of ventricular arrhythmias. Cardiovasc. Res. 
69:348–358.
34. Vander Salm, T.J. 2000. Unusual primary tumors of the heart. Semin. 
Thorac. Cardiovasc. Surg. 12:89–100.
35.  Yasuda, T., R.D. Weisel, C. Kiani, D.A. Mickle, M. Maganti, and R.K. 
Li. 2005. Quantitative analysis of survival of transplanted smooth muscle 
cells with real-time polymerase chain reaction. J. Thorac. Cardiovasc. 
Surg. 129:904–911.
36.  Deschamps, A.M., and F.G. Spinale. 2005. Matrix modulation and heart fail-
ure: new concepts question old beliefs. Curr. Opin. Cardiol. 20:211–216.
37. Laugwitz, K.L., A. Moretti, J. Lam, P. Gruber, Y. Chen, S. Woodard, 
L.Z. Lin, C.L. Cai, M.M. Lu, M. Reth, et al. 2005. Postnatal isl1+ 
cardioblasts enter fully diff   erentiated cardiomyocyte lineages. Nature. 
433:647–653.
38.  Fleischmann, M., W. Bloch, E. Kolossov, C. Andressen, M. Muller, G. 
Brem, J. Hescheler, K. Addicks, and B.K. Fleischmann. 1998. Cardiac 
specifi  c expression of the green fl  uorescent protein during early murine 
embryonic development. FEBS Lett. 440:370–376.
39. Fleischmann, B.K., Y. Duan, Y. Fan, T. Schoneberg, A. Ehlich, N. 
Lenka, S. Viatchenko-Karpinski, L. Pott, J. Hescheler, and B. Fakler. 
2004. Diff   erential subunit composition of the G protein-activated 
  inward-rectifi  er potassium channel during cardiac development. J. Clin. 
Invest. 114:994–1001.
40.  Igelmund, P., B.K. Fleischmann, I.R. Fischer, J. Soest, O. Gryshchenko, 
M.M. Bohm-Pinger, H. Sauer, Q. Liu, and J. Hescheler. 1999. Action 
potential propagation failures in long-term recordings from embry-
onic stem-cell derived cardiomyocytes in tissue culture. Pfl  ugers Arch. 
437:669–679.
41. Stett, A., U. Egert, E. Guenther, F. Hofmann, T. Meyer, W. Nisch, 
and H. Haemmerle. 2003. Biological application of microelectrode 
arrays in drug discovery and basic research. Anal. Bioanal. Chem. 
377:486–495.
42. Pillekamp, F., M. Reppel, V. Dinkelacker, Y. Duan, N. Jazmati, 
W. Bloch, K. Brockmeier, J. Hescheler, B.K. Fleischmann, and R. 
Koehling. 2005. Establishment and characterization of a mouse embry-
onic heart slice preparation. Cell. Physiol. Biochem. 16:127–132.